Back

SGLT2 inhibitors should be first-line treatment in HFrEF: pro

26 August 2023 (08:30 - 08:45)
Organised by: Logo
Congress Presentation Part of: Great Debate: controversies in the contemporary management of HFrEF Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Milton Packer

Baylor University Medical Center, Dallas (United States of America)

5 More presentations in this session

Presentation thumbnail
SGLT2 inhibitors should be first-line treatment in HFrEF: con
Professor J. Cleland (Glasgow, GB)
Slides Video
Presentation thumbnail
SGLT2 inhibitors should be first-line treatment in HFrEF - discussion
Video
Presentation thumbnail
There is a role for anticoagulation in patients with HFrEF in sinus rhythm: pro
Associate Professor F. Marin (Murcia, ES)
Slides Video
Presentation thumbnail
There is a role for anticoagulation in patients with HFrEF in sinus rhythm: con
Doctor C. Reddin (Galway, IE)
Slides Video
Presentation thumbnail
There is a role for anticoagulation in patients with HFrEF in sinus rhythm - discussion
Video

Access the full session

Session thumbnail
Great Debate: controversies in the contemporary management of HFrEF
Video

The Event

Event poster

ESC Congress 2023

26 August 2023 08:30 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitors should be first-line treatment in HFrEF: con
thumbnail
Congress Presentation
SGLT2 inhibitors should be first-line treatment in HFrEF - discussion
thumbnail
Congress Presentation
De novo heart failure: when to start treatment with an ARNI and SGLT2i

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources